← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants
pivagabine
N06AX15
Adult Dosing
- 300 mg to 600 mg orally divided into two to three daily doses
- Duration of treatment typically ranges from 2 to 6 weeks depending on clinical response
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
- Not recommended for use in children
Indications
- Management of asthenia and psycho-organic syndromes
- Treatment of depressive states with apathy and psychomotor retardation
Mechanism of Action
- GABA derivative that acts as a GABAb receptor agonist
- Exerts mild psychostimulatory, nootropic, and anxiolytic effects
- Improves cerebral energy metabolism and neuronal resistance to hypoxia
Contraindications
- Hypersensitivity to pivagabine or any component of the formulation
- Severe hepatic impairment
- Severe renal impairment
- Acute psychosis
Adverse Reactions
- Sleep disturbances (insomnia or drowsiness)
- Irritability and anxiety
- Gastrointestinal discomfort (nausea, epigastric pain)
- Allergic skin reactions (rash, pruritus)
Drug Interactions
- Potentiation of central nervous system depressants (barbiturates, benzodiazepines, alcohol)
- May alter the efficacy of anticonvulsants when co-administered
- Enhancement of psycho-stimulant effects when combined with other nootropics
Curated Content: Needs Vetting Before Put to Clinical Use